complicado mecanismo de acción antitumoral como con sus efectos .. inhibidores de la topoisomerasa II (doxorrubicina, etopósido. mecanismo de acción de antineoplasicos. AV Doxorrubicina (antraciclina). – Lesión del ADN. –Inhibición topoisomerasa II. –Vía intravenosa. Abraxane (nombre genérico: paclitaxel unido a albúmina (nab-paclitaxel)) · Adriamicina (nombre genérico: doxorrubicina) · Carboplatino.
|Published (Last):||17 March 2015|
|PDF File Size:||5.1 Mb|
|ePub File Size:||8.23 Mb|
|Price:||Free* [*Free Regsitration Required]|
EPIRUBICINA EN VADEMECUM
Patients who have already received the maximum cumulative dosage of anthracyclines should not receive intravesicle epirubicin.
In two European phase III trials comparing epirubicin FEC and doxorubicin CAF in combination with cyclophosphamide and fluorouracil for the treatment of breast cancer, the patients treated with epirubicin had similar response and survival rates as patients treated with doxorubicin. Men may experience spermatogenesis inhibition.
Epirubicin has been designated an orphan drug by the FDA for this indication. However, later events several months to years after ending treatment have been reported. Epirubicin-induced cardiomyopathy and congestive heart failure CHF is associated with the cumulative dose of epirubicin.
This reaction causes erythema, exfoliative dermatitis, pain, and burning, similar to that experienced with the original radiation mefanismo.
For the adjuvant treatment of breast cancer: A second woman with breast cancer metastatic to the liver received fluorouracil, cyclophosphamide and epirubicin but was removed from the trial due to the pregnancy.
Br J Cancer ; The correct dose of epirubicin will vary from protocol to protocol.
Doxorrubicina – Viquipèdia, l’enciclopèdia lliure
Conjunctivitis and keratitis have been reported with epirubicin chemotherapy. Epirubicin has also been studied in combination with vinorelbine and as a single-agent therapy. Dosage For the adjuvant treatment of breast cancer: The esophagus can be especially sensitive. Epirubicin is administered intravenously. This membrane protein functions as an energy-dependant drug efflux pump in resistant cells.
Due to the thrombocytopenic effects of epirubicin, an additive meanismo of bleeding may be adcion in patients receiving concomitant anticoagulants, NSAIDs, platelet inhibitors, including aspirin, strontium chloride, and thrombolytic agents.
Symptoms may last up to an hour and may be treated with steroids, antihistamines and ice packs. The red urine should meccanismo be confused with hematuria. Due to the risk of long-term cardiotoxicity, it has been recommended that children treated with anthracyclines should undergo screening with ECGs and echocardiograms every 2 years and hour continuous ECGs and radionucleide angiograms every 5 years.
Paclitaxel vs epidoxorubicin plus paclitaxel as second-line therapy for platinum-refractory and -resistant ovarian cancer. Because antineoplastic agents exert their toxic effects against rapidly growing cells, such as hematopoietic progenitor cells, sargramostim, GM-CSF, and doxorrubiciha, G-CSF, are contraindicated for use in patients within 24 hours of treatment with antineoplastic agents.
Use care to avoid accidental exposure to epirubicin during preparation, handling, and administration. Hyperpigmentation of the oral mucosa may also occur. Unfortunately, trifluoperazine and verapamil must be given in toxic doses to achieve this positive effect. Patients with prior treatment with radiation therapy or anthracyclines may have decreased ability to tolerate trastuzumab therapy.
Estimates for postponing vaccination vary from 3 months to 1 year following discontinuation of treatment depending of the type of antineoplastic agent used and the disease state of the patient.
It is thought that myocardial damage and ventricular dysfunction progress and lead to late-onset cardiac dysfunction following treatment with anthracyclines. The coadministration of paclitaxel or docetaxel did not affect the pharmacokinetics of mecanis,o when epirubicin was given immediately following the taxane.
Attempt to aspirate the drug prior to removing the needle. This may manifest as reduced LVEF, tachycardia, dyspnea, pulmonary edema, hepatomegaly, ascites, pleural effusion, or gallop rhythm.
Regrowth of hair usually resumes 3 weeks after therapy has been discontinued. The glucuronide metabolites of epirubicin and epirubicinol are not active, but the glucuronide metabolism does divert epirubicin from free radical formation, which may reduce cardiotoxicity.
As this can be a progressive injury, appropriate long-term follow-up is required. Symptoms of extravasation are usually immediate although extravasations into chest wall tissue are less acutely symptomatic.
Epirubicin is an anthracycline chemotherapy agent and is the 4′-epimer of doxorubicin and a semi-synthetic derivative of daunorubicin. Females and children may be more sensitive to the cardiotoxic effects of anthracyclines.